Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes the first known instance of hair loss linked to agomelatine, which resolved after the drug was discontinued.

Agomelatine might help stop hair loss caused by valproate.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

Agomelatine might help reduce hair loss caused by valproate.

In this animal study, agmatine exhibited a protective effect against seizures related to hormone fluctuations, with results suggesting that its anticonvulsant properties may involve interactions with central neurosteroids in female rats experiencing progesterone withdrawal.

This study found that early life stress significantly affects hedonic sensitivity to high-palatable food by altering gonadal hormones in prenatally-stressed male and female rats, with sex-dependent changes in reward-related behaviors and neurochemistry.

This review highlights the promising potential of microemulsions and nanoemulsions in (trans)dermal drug delivery, noting a gap in understanding their distinct mechanisms and composition-related effects on skin permeability, while emphasizing the limited clarity on mesostructures and cosolvent impacts.

This study found that the antidepressant-like effect of fluoxetine in mice was only observed when a 5-minute pretest session was conducted, and this effect was blocked by the TSPO antagonist PK11195.

This chapter reviews existing knowledge about melatonin's MT₁ and MT₂ receptors in human tissues, discussing their established and potential functions, but reports no new clinical findings.

This case report describes a 21-year-old male who experienced sertraline-induced diffuse hair loss that improved after discontinuing the medication.

This study found that topical melatonin significantly improved hair density and reduced the severity of androgenetic alopecia in men and women.

This study suggests that combining monoammonium glycyrrhizinate/glycine/DL-methionine tablets with 5% carpronium chloride may reduce alopecia areata area more effectively than carpronium chloride alone, particularly in patients with allergic factors.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.

RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.

In this study, cetirizine hydrochloride was formulated into niosomal and cubosomal gels, showing potential for off-label use in treating androgenic alopecia due to effective skin permeation and acceptable safety profiles; cubosomal gels exhibited superior permeation compared to niosomal gels.

Olanzapine reduces stress-related anxiety in rats when given acutely.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

This study found that melatonin-loaded nanoparticles improved antidepressant effects and HPA axis regulation in pinealectomized rats, compared to free melatonin, through controlled-release properties.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

In this animal study, the methanolic extract of Crataeva nurvala leaves was found to possess sedative and anxiolytic properties, potentially linked to GABAergic activity and certain neuroactive compounds.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

In this study, cetosomal-based minoxidil solutions, with and without finasteride, were observed to be effective and tolerable treatments for androgenetic alopecia in adults, providing a potential alternative to traditional alcoholic formulations.

This review discusses the lack of long-term clinical studies on metformin's cardiovascular benefits in women with polycystic ovary syndrome, highlighting lifestyle changes as a crucial management strategy for reducing associated risks.

In this retrospective study at Toyama University Hospital, amoxapine was reported to significantly improve semen volume, sperm concentration, and total sperm count in 17 men with ejaculatory disorders, with no observed side effects over an average of 13 months of therapy.

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

In this laboratory study, Cucumis melo var. makuwa leaf extract significantly reduced DHT-induced apoptosis in human dermal papilla cells by modulating androgen receptor activity and gene expression, suggesting potential as a therapy for androgenetic alopecia.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.